This prospective observational study assessed the impact of Perutaneous Electrical Nerve Field Stimulation (PENFS) on 31 children (mean age 15.7 years, 80.6% female) with pain-related Disorders of Gut-Brain Interaction (DGBIs).
Frontiers in Pain Research · 7 authors, 3 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This prospective observational study assessed the impact of Perutaneous Electrical Nerve Field Stimulation (PENFS) on 31 children (mean age 15.7 years, 80.6% female) with pain-related Disorders of Gut-Brain Interaction (DGBIs).
This prospective observational study assessed the impact of Perutaneous Electrical Nerve Field Stimulation (PENFS) on 31 children (mean age 15.7 years, 80.6% female) with pain-related Disorders of Gut-Brain Interaction (DGBIs). Patients received weekly PENFS therapy for four weeks. At week 4, patient-reported outcomes showed significant improvements in abdominal pain, nausea severity, functional disability, somatization, and anxiety (p < 0.05). Parent-reported outcomes indicated significant improvements in child quality of life (QoL) for physical function, psychosocial function, and the generic core scale, as well as reduced abdominal pain, functional disability, and somatization (p < 0.05). Average PROMIS Global Health scores significantly improved according to both patient and parent reports (p < 0.05). A key limitation is that children's QoL remained significantly lower than that of healthy controls both at baseline and after treatment. The study suggests PENFS may enhance QoL and reduce symptoms in this pediatric population, though the effect on self-perceived QoL is less clear.